Diabetic nephropathy
Conditions
Interventions
Experimental group:Take polysaccharide iron complex capsules (Hongyuanda, Shanghai Pharmaceutical Group, Qingdao Guofeng Pharmaceutical Co., Ltd., each capsule contains 150mg of iron), 300mg each time
Control group:None
Sponsors
Yaan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=18 years, non-dialysis diabetic nephropathy patients, estimated glomerular filtration rate (GFR) of 15-90 ml/min/1.73 m2 (calculated by MDRD formula); 2. Presence of renal anemia, hemoglobin (hemoglobinHb) level <=120g/L for women and <=130g/L for men; 3. Ferritin (serumferritin SF) < 500 ng/ml and transferrin saturation (TSAT) < 50%; 4. Not treated with iron or erythropoiesis-stimulating agents (ESAs) in the 8 weeks prior to inclusion.
Exclusion criteria
Exclusion criteria: 1. Anemia and active systemic infection caused by any reason other than iron deficiency in CKD; 2. Intolerance to polysaccharide iron complex or any of its components; 3. Pregnant or lactating; 4. Anticipated possible dialysis or transplantation during the study; 5. Positive fecal occult blood test; 6. Chronic liver disease; 7. Hypertension (systolic blood pressure > 180mmHg or diastolic blood pressure >110mmHg) with New York Heart Association class IV heart failure and poor control; 8. Any malignant tumor (except basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) within the past 3 years; 9. There are events that may affect follow-up, such as the presence of drug or alcohol abuse, severe mental disorders, severe respiratory diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin; | — |
Countries
China
Contacts
Public ContactHe Yi
Yaan People's Hospital
Outcome results
None listed